StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > IR

<< Previous

Bullboard Posts

Next >>

Comment by brad129on Nov 20, 2020 12:40pm

93 Views

Post# 31941430

RE:RE:RE:RE:RE:IR

Good question, my guess is they can reevaluate the offering as they just did with the warrants, not sure, apparently they had 1/2 filled so hopefully they are committed to the future of the company.

Bully88 wrote: Genuine question/ concern here,

Do major institutions invest in a PP at a certain price if the stock is strading .10 - .15 cents below the offering?

if an institution has agreed to buy at a certain price but the shares go down the way they have today, do they have the option to back out and just buy at the lower price?

would this be a risk of not having anybody participate in the offering?

thank you for your informed, eductated responces.

Cheers,

Bully